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MembraneExpression of the frontotemporal dementia-related tau mutation, P301L, at physiological levels in adult mouse
brain (KI-P301L mice) results in overt hypophosphorylation of tau and age-dependent alterations in axonal
mitochondrial transport in peripheral nerves. To determine the effects of P301L tau expression in the central ner-
vous system, we examined the kinetics ofmitochondrial axonal transport and tau phosphorylation in primary cor-
tical neurons from P301L knock-in (KI-P301L) mice. We observed a signiﬁcant 50% reduction in the number of
mitochondria in the axons of cortical neurons cultured from KI-P301L mice compared to wild-type neurons.
Expression of murine P301L tau did not change the speed, direction of travel or likelihood of movement of
mitochondria. Notably, the angle that deﬁnes the orientation of the mitochondria in the axon, and the volume of
individualmovingmitochondria,were signiﬁcantly increased in neurons expressing P301L tau.We found thatmu-
rine tau phosphorylation in KI-P301Lmouse neuronswas diminished and the ability of P301L tau to bind tomicro-
tubules was also reduced compared to tau inwild-type neurons. The P301L mutation did not inﬂuence the ability
of murine tau to associate with membranes in cortical neurons or in adult mouse brain. We conclude that P301L
tau is associated with mitochondrial changes and causes an early reduction in murine tau phosphorylation in
neurons coupled with impaired microtubule binding of tau. These results support the association of mutant tau
with detrimental effects on mitochondria and will be of signiﬁcance for the pathogenesis of tauopathies.
Crown Copyright © 2015 Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
The microtubule-associated protein tau is expressed mainly in neu-
ronswhere it stabilisesmicrotubules and is involved in neurite outgrowth
(Hernandez et al., 2002; Lee and Rook, 1992). The microtubule-binding
domain of tau is located in its carboxy-terminal half and tubulin binding
is regulated by tau phosphorylation state (Bramblett et al., 1993;ay 18; EGFP, enhanced green
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r Inc. This is an open access article uBusciglio et al., 1995). The amino-terminal projection domain of tau inter-
actswith components of the plasmamembrane and is also affected by tau
phosphorylation state (Bramblett et al., 1993; Busciglio et al., 1995; Pooler
et al., 2012).
The humanMAPT gene is located on chromosome 17 and comprises
16 exons. Exclusion or inclusion of exon 10 gives rise to tau isoforms
with three (3R) or four (4R) microtubule binding repeats (Andreadis
et al., 1992; Goedert et al., 1989). In the developing brain, 3R tau iso-
forms predominate, whereas in adult human brain 3R and 4R tau are
expressed in approximately equal amounts. Mutations in MAPT cause
frontotemporal dementia with parkinsonism linked to tau mutations
on chromosome 17 (FTDP-17T) (Hutton et al., 1998; Poorkaj et al.,
1998; Spillantini et al., 1998), characterised by intraneuronal aggregates
of insoluble, highly phosphorylated tau. FTDP-17T and other neurode-
generative diseases with CNS tau aggregates are collectively referred
as tauopathies (Ballatore et al., 2007; Gallo et al., 2007). Disease-
associated mutations in MAPT occur as exonic missense mutations
(e.g. P301L), silent mutations (e.g. N279N), or intronic mutations
that affect exon 10 splicing regulatory elements and thereby alter the
4R/3R tau isoform ratio (D'Souza et al., 1999; Grover et al., 1999;
Spillantini et al., 1998). However, not all of the known mutations innder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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mechanisms that link these mutations to the observed pathological
and clinical features of the tauopathies are not well understood.
Many transgenic mouse lines that model tauopathies have been
generated by overexpression of either wild-type or FTDP-17T mutant
tau (reviewed in Denk andWade-Martins, 2009; Noble et al., 2010). Ax-
onal degeneration and transport impairments have been described in
several of thesemousemodels, withmore frequent mature ﬁlamentous
tau pathology occurring in mice overexpressing mutant tau. However,
differences in the expression of exogenous tau due to the use of heterol-
ogous promoters, and an imbalance in tau isoform expression by over-
expression of individual isoforms of human tau, are signiﬁcant
limitations in many of these models. For example, P301L or P301S tau
expressed under the control of different promoters including prion
(Lewis et al., 2000), Thy 1 (Allen et al., 2002; Terwel et al., 2005) and
calcium-calmodulin kinase II (Santacruz et al., 2005), each result in
different tau expression patterns and variable phenotypic outcomes.
We created a transgenic tau knock-in (KI) mouse expressing physi-
ological levels of murine tau and harbouringmutant P290L tau, equiva-
lent to human P301L tau (Gilley et al., 2012).We used thismouse line to
investigate the impact of P301L tau on FTDP-17T-associated tau pathol-
ogy and neural dysfunction (Gilley et al., 2012). Overt tau pathologywas
not observed and interestingly, we found that the overall level of tau
phosphorylation was reduced in adult KI-P301L mice (Gilley et al.,
2012). However, these transgenic mice exhibited age-dependent
changes in mitochondrial axonal transport.
Mitochondria are highly dynamic organelles that undergo continu-
ous bi-directional movements, combined with frequent ﬁssion and
fusion events (Schulz et al., 2012). Dysregulation ofmitochondrial activ-
ity and transport is associated with a number of age-related neurode-
generative disorders (De Vos et al., 2008; Exner et al., 2012; Lin and
Beal, 2006). Recent ﬁndings also implicate defective mitochondrial
function and dynamics induced by amyloid beta-peptide and/or tau in
the pathogenesis of Alzheimer's disease (Amadoro et al., 2014; Eckert
et al., 2013; Manczak and Reddy, 2012).
To gain insight into themechanisms underlying the axonal transport
defect observed in KI-P301Lmice, we characterised the effects of tau on
axonal mitochondrial transport in primary cortical neurons and investi-
gated tau phosphorylation. We found that the total number of
mitochondria in axonswas reduced and the volume of individualmotile
mitochondria was signiﬁcantly increased in neurons derived from
KI-P301L mice. We also found that tau hypophosphorylation observed
in adult mouse brain was recapitulated in cultured cortical neurons.
Our results suggest that physiological expression of mutant P301L tau
decreases tau phosphorylation and reduces the number of axonal
mitochondria at a very early stage of development, supporting the asso-
ciation of mutant tau with dysregulation of mitochondrial activity.
Material and methods
Mouse maintenance and generation
All mice were bred and housed in accordance with the UK Home
Ofﬁce Animals (Scientiﬁc Procedures) Act, 1986. KI-P301L mice were
generated in a C57BL/6 background by (Gilley et al., 2012). Brieﬂy, the
human FTDP-17 P301L mutation was targeted to the homologous
codon in exon 10 of the mouseMapt gene— P290 in 2N4R murine tau.
Correct targeting of the knockin allele was veriﬁed by Southern blotting
and mice were genotyped by Southern blotting or PCR. Expression and
normal splicing ofMaptmessenger RNA derived from the “P301L” tau
knockin allele was conﬁrmed by RT-PCR (Gilley et al., 2012).
Cortical neuronal culture and transfection
Embryonic day 18 (E18) wild-type and P301L tau-expressing mouse
cortical neurons were cultured as described previously (Cuchillo-Ibanezet al., 2008). Cortical neuronswere transfected using either calciumphos-
phate (Promega,Madison, USA) or Lipofectamine 2000 (Invitrogen, Carls-
bad, CA, USA) following the manufacturers' instructions.
Time-lapse imaging and analysis of mitochondria in transfected neurons
E18 rat cortical neurons 7DIVwere co-transfectedwith plasmids ex-
pressing enhanced green ﬂuorescent protein (EGFP) or DsRed-Mito
(Invitrogen, Carlsbad, CA, USA) and time-lapse images were recorded
after 24–48 h. Coverslips were placed in a sealed chamber and the
cells were maintained at 37 °C using an objective heater (Tempcontrol
37–2, Zeiss, Jena, Germany) and “The Box” Microscope Temperature
Control System (Life Imaging Services Basel, Switzerland) on the stage
of an Axiovert 200 M Zeiss microscope equipped with a Lambda LS
Xenon-Arc light source (Sutter Instrument Company, Novato, CA,
USA). Images ofmitochondrialmovementwere collected at 3 s intervals
for 10 min using a Plan-ApoChromat 40 × 1.4 NA oil immersion objec-
tive, an EGFP/DsRed ﬁlter set (Chroma Technology Corp., Rockingham,
VT, USA) and an AxioCamMRm camera. Image analysis was performed
with ImageJ developed by Wayne Rasband (NIH, Bethesda, MD, USA;
http://rsb.info.nih.gov/ij/). EGFP expression enabled identiﬁcation of
transfected neurons and tracing of axons from the neuronal cell body
to the growth cone, aswe reported previously (Morotz et al., 2012). Mi-
tochondrial kinetic parameters were assessed using Difference Tracker,
a programme consisting of 2 plugins for the ImageJ software (Andrews
et al., 2010). The contrast and despeckle functions were applied to all
images. The difference ﬁlter plugin was used with minimum difference
10 and difference frame onset 4, and for the mass particle tracker plugin
the settings for the initial ﬂexibility and subsequent ﬂexibility were 25
and 20, respectively. Quantitation and statistical analyses (Student t-test)
were performed using Excel and Prism software (GraphPad Software
Inc., La Jolla, CA, USA). Image analysis for parameters (angle, average size,
circularity, perimeter, solidity, primary axis and secondary axis) of all
mitochondria (stationary and motile) was performed using ImageJ.
Gel electrophoresis and Western blots
106 neurons per well of a 6-well plate were rinsed with phosphate-
buffered saline (PBS) at 4 °C and cells were scraped into hot (2×)
Laemmli sample buffer. Proteins were separated on 10% (w/v) sodium
dodecyl sulphate (SDS) polyacrylamide gels and transferred to nitrocel-
lulose. Membranes were probed with antibodies to total tau (rabbit
polyclonal, DAKO, Glostrup, Denmark) and monoclonal Tau5 (Sigma-
Aldrich, Gillingham, Dorset, UK), phosphorylated tau (polyclonal
pT231 and pS404, Cell Signalling, Danvers, MA, USA and PHF1, a kind
gift from Professor Peter Davies, Albert Einstein College of Medicine,
New York), dephosphorylated tau (monoclonal Tau1, Millipore, Billeri-
ca, MA, USA), PP1 and PP2 (Santa Cruz, Dallas, Texas, USA), Opa1 (BD
Transduction Laboratories), Mfn2 and monoclonal β-actin (both from
Sigma, Gillingham, Dorset, UK). Antigens were visualised using an
Odyssey scanner (Li-Cor Biosciences, Lincoln, Nebraska, USA).
Microtubule binding assay
Assays for microtubule binding of tau were performed as described
previously (Rodriguez-Martin et al., 2013). Wild-type and KI-P301L-
expressing 12 DIV cortical neurons were rinsed in warm PBS, and
suspended in warm microtubule-stabilising buffer (80 mM PIPES/KOH
pH 6.8, 1 mM GTP, 1 mM MgCl2, 1 mM ethylene glycol-bis(2-
aminoethyl)-N,N,N′,N′-tetraacetic acid (EGTA), 0.5% (w/v) Triton X-100,
30% (v/v) glycerol), containing 1 mM phenylmethylsulfonylﬂuoride,
Complete protease inhibitor (Roche, Basel, Switzerland), 0.5 μM okadaic
acid (Calbiochem Billerica, MA, USA) and 10 μM taxol (Sigma-Aldrich,
Gillingham, Dorset, UK). Cell suspensions were centrifuged at 5000 g for
10 min at ambient temperature and an aliquot of the supernatant was
retained as the post-nuclear lysate (input). The remaining post-nuclear
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supernatant, containing unbound tau, was retained and the pellet, con-
taining microtubule-bound tau, was rinsed twice, and resuspended in
microtubule-stabilising buffer. Proteins in each fraction were separated
on 10% (w/v) SDS polyacrylamide gels and blots were probed with tau
polyclonal antibody (DAKO, Glostrup, Denmark), as above.
Dephosphorylation of neuronal lysates
Lambda phosphatase (New England Biolabs, Ipswich, MA, US) was
used to dephosphorylate neuronal cell lysates as described (Hanger
et al., 2002).
Cell fractionation
Mouse cortical neurons cultured on 6-well plates were lysed in
hypotonic buffer (10mM sodium bicarbonate containing 20mg/mL de-
oxyribonuclease I (DNase I), 1mM sodiumorthovanadate and complete
protease inhibitor cocktail (Roche, Mannheim, Germany)), disrupted by
sonication (ﬁve strokes with probe sonicator) on ice and processed as
previously described (Pooler et al., 2013). Brieﬂy, cell lysates were cen-
trifuged at 720 g for 5 min at 4 °C, and the resultant supernatant was
centrifuged at 100,000 g for 1 h at 4 °C. The ﬁnal supernatant (cytosolic
fraction) and the pellet (membrane fraction) were resuspended in
Laemmli sample buffer, and analysed on Western blots probed with
total tau polyclonal antibody (DAKO) and dephosphorylated tau
antibody Tau1, as above.
RT-PCR
Total RNA was isolated from primary cortical neurons using TRIzol
reagent (Invitrogen, Carlsbad, CA, USA). Reverse transcription was per-
formed using the Multiscribe RT kit (Applied Biosystems, Carlsbad, CA,
USA) with random oligo(dT). The reverse transcription conditions
were 10 min at 25 °C, 30 min at 48 °C, and a ﬁnal step of 5 min at 95
°C. Reverse-transcribed RNA was ampliﬁed by PCR under the following
conditions: 95 °C for 2min, 30 cycles of 30 s at 94 °C, 30 s at 65 °C, 20 s at
72 °C and a ﬁnal extension step for 10min at 72 °C. The sequences of the
primers used were: forward primer (exon 9), 5′-CTGAAGCACCAGCCAG
GAGG-3′; reverse primer (exon 13), 5′-TGGTCTGTCTTGGCTTTGGC-3′.
The predicted sizes for the corresponding PCR products were 274 base
pairs for 3R tau and 367 base pairs for 4R tau. RT-PCR products were
separated by electrophoresis in 1.5% (w/v) agarose gels and stained
with ethidium bromide.
Results
Reduction of axonal mitochondrial number in P301L tau neurons
In a previous in vivo study, we found that adult KI-P301L tau mice
exhibit age-dependent differences in axonal mitochondrial transport
in isolated tibial nerve (Gilley et al., 2012).Whilst retrogrademovement
of mitochondria was unchanged, anterograde mitochondrial ﬂux
was increased in younger KI-P301L tau mice and decreased in older
mice, relative to their wild-type counterparts. To investigate the age-
dependency of these effects, we determined the effect of the P301L
tau mutation on mitochondria in cultured neurons. Mouse cortical
neurons 7 DIV (days in vitro) from wild-type and KI-P301L tau mice
were co-transfected with plasmids expressing a mitochondrial targeting
sequence fused to DsRed (DsRed-Mito), to labelmitochondria, and EGFP,
to visualise cell bodies and axons. Neurons expressing low levels of the
exogenous proteins were selected to avoid potential artefacts due to
over-expression. Movement of mitochondria was recorded at 3 s inter-
vals over a period of 10 min using time-lapse microscopy at 24–48 h
after transfection (Cuchillo-Ibanez et al., 2008; Morotz et al., 2012).
Time-lapse movies were transformed into kymographs (wild-type,n = 28, P301L tau, n = 15) and the number of mitochondria present
in the portion of axons recordedwas calculated (Fig. 1A, B). Quantitation
of the total mitochondria in axons revealed a 50% reduction in the
number of mitochondria per μm in axons of neurons expressing P301L
tau compared with wild-type tau (Fig. 1C). Interestingly, we found that
the angle that deﬁnes the orientation of mitochondria in the axon was
increased in neurons expressing P301L tau (Fig. 1D). In contrast, there
were no differences between the average size, circularity, perimeter,
solidity, primary axis or secondary axis of mitochondria in neurons
expressing wild-type and P301L tau (Fig. 1E–J).
The number of stationary and motile mitochondria moving in both
anterograde and retrograde directions was determined in wild-type
and P301L tau-expressing neurons and expressed as a proportion of
the total number of mitochondria (Table 1). This analysis revealed
that approximately 20% of mitochondria aremotile and 80% are station-
ary in neurons expressing either wild-type or mutant P301L tau. Of the
moving mitochondria, 58% and 57% travelled anterogradely, and 42%
and 43% travelled retrogradely, with respect to wild-type and P301L
tau. Therefore, the presence of P301L tau did not inﬂuence the relative
proportions of motile and stationary mitochondria or their direction of
axonal transport.
Wenext characterised the transport parameters ofmotilemitochon-
dria by analysing time-lapse images using the Difference Tracker
programme. This programme provides an automated analysis of axonal
transport parameters including average and maximum speeds and
volumes of motile, but not stationary, mitochondria travelling in both
anterograde and retrograde directions (Fig. 2A). The number of mito-
chondria moving in each direction was approximately equal in wild-
type and KI-P301L tau neurons (Fig. 2B). The average and maximal
speeds of motile mitochondria moving in each direction were also
similar in wild-type tau and P301L tau-expressing neurons (Fig. 2B).
However, the volume of individual mitochondria moving in both anter-
ograde and retrograde directionswas signiﬁcantly increased in neurons
expressing P301L tau (Fig. 2B), which could be related to a defect in mi-
tochondrial fusion or ﬁssion. Lysates of 8 DIV wild-type and P301L
neurons were analysed on Western blots probed with an antibody
recognising optic atrophy 1 (Opa1) and mitofusin 2 (Mfn2), which are
required for mitochondrial fusion (Fig. S1). No differences were detect-
ed in the amount of Opa1 andMfn2 present inwild-type and P301L tau-
expressing neurons. This result suggests that changes in mitochondrial
fusion are unlikely to be responsible for the observed increase in
mitochondrial volume due to the P301L tau mutation. However, it is
worth noting that because only 20% of the mitochondria were motile
in these neurons, possible changes in Opa1 and Mfn2 may not have
been detectable using this approach.
Taken together, our quantitative analysis of total mitochondria and
moving mitochondria in cultured neurons suggests that the P301L tau
mutation causes a dramatic reduction in the overall number of axonal
mitochondria. P301L tau also increases the volume of individual motile
mitochondria, without affecting their speed, likelihood of movement or
direction of movement.
P301L tau is hypophosphorylated in cortical neurons
Our previous study of adult KI-P301L mice reported changes in
axonal mitochondrial transport and a reduction in tau phosphorylation
in adult mouse brain. To examine tau phosphorylation status in the
cortical neurons used for the axonal transport studies, 8 DIV wild-type
and KI-P301L tau neuronal lysates were probed with antibodies to tau
and β-actin on Western blots (Fig. 3A). The tau antibodies recognise
total tau (DAKO, Tau5), dephosphorylated tau (Tau1 [S199/S202]), or
phosphorylated tau (pT231, pS404, PHF1 [S396/404]). The amount of
tau was quantiﬁed and expressed relative to β-actin, whereas
phospho-tau was standardised to total tau.
Tau inwild-type neurons appears as amajor species of ~50 kDa along
with a minor, slower-migrating band (Fig. 3A, arrow). Quantiﬁcation of
Fig. 1. P301L tau reduces axonal mitochondria number and increases mitochondrial orientation angle in axons. Representative images of (A) wild-type (WT) and (B) knock-in P301L
(P301L) straightened time-lapse movie. (C) Quantiﬁcation of the number of mitochondria per μm axon. (D–J) Detailed analyses of time-lapse recordings: angle (D), average size (E), cir-
cularity (F), perimeter (G), solidity (H), primary axis (I) and secondary axis (J) of all mitochondria (stationary and motile) are shown as mean ± SEM (n= 28 for WT, n = 15 for P301L,
Student t-test, P b 0.01**, P b 0.001***).
Table 1
Motility of mitochondria in neurons expressing wild-type and KI-P301L tau.
Neuronal genotype % Anterograde % Retrograde % Stationary
Wild-type tau 11.2 ± 1.5 (28) 8.0 ± 1.1 (28) 80.7 ± 1.7 (28)
KI-P301L tau 12.5 ± 2.5 (15) 9.6 ± 2.1 (15) 77.9 ± 3.0 (15)
Time-lapse recordings of mitochondrial transport in wild-type and knock-in P301L
(KI-P301L) tau neurons were tracked. The percentage of motile mitochondrial travelling
in each direction, and percentage of stationary mitochondria are shown. Data are
expressed as mean ± SEM (n).
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pared to wild-type neurons (Fig. 3B). However, the total amount of tau
at 8DIVwas similar in bothwild-type and P301L tau-expressing neurons
(Fig. 3C). Quantiﬁcation of tau phosphorylation did not reveal any statis-
tically signiﬁcant changes at the epitopes recognised by Tau1, pT231,
pS404 or PHF1 antibodies in wild-type or P301L tau-expressing neurons
(Fig. S2). Taken together, these results show that wild-type tau is phos-
phorylated at residues 199/202, 231, 396/404. Thus, these residues are
not affected by the presence of P301L tau, despite KI-P301L tau neurons
Fig. 2.Mitochondrialmovement kinetics are not affected in P301L tau axons. (A) Overviewof themethodology used formitochondrial transport analysis inmouse cortical neurons. Image
stacks of individual axonswere generated using the “Straighten” ImageJ plugin.Motilemitochondriawere tracked using Difference Tracker plugins for ImageJ, showing anterograde trans-
port (yellow shadow) and retrograde transport (blue shadow). (B) Quantiﬁcation of the number, average speed, maximum speed and average volume per particle ofmotilemitochondria
in wild-type (WT) and P301L tau-expressing neurons. Data are shown as mean ± SEM (n = 28 for wild-type, n = 15 for P301L, Student t-test, P b 0.01**).
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suggesting that the reduced tau phosphorylation induced by P301L tau
does not result from changes at the epitopes examined here.
In embryonic day 18 (E18) brain, tau consists primarily of the
smallest tau isoform, 0N3R. Other tau isoforms comprising both 3R
and 4R species become apparent only at later stages of development
(Hernandez et al., 2004). Since alternative splicing of 3R and 4R tau iso-
forms could contribute to the altered band pattern and electrophoretic
migration of P301L tau, we investigated whether P301L tau affectsalternative splicing of tau in cultured neurons. The proﬁle of tau
isoforms in wild-type and P301L tau-expressing neurons at 5, 8, 12
and 14 DIV was analysed on Western blots following neuronal lysis
and dephosphorylation (Hanger et al., 2002). The results show that
there is no apparent difference in the pattern of dephosphorylated tau
bands in neurons from wild-type or KI-P301L tau mice (Fig. 3D). Fur-
thermore, longer culture duration results in the appearance of larger
tau isoforms with reduced mobility (Fig. 3D), in line with the expected
increased production of 4R tau isoforms following extended culture
Fig. 3. P301L tau is hypophosphorylated in mouse cortical neurons. (A) Lysates of wild-type (WT) and knock-in P301L (KI-P301L) tau neurons at 8 days in vitro (DIV) were analysed on
Western blots probedwith antibodies against total tau (DAKO and Tau5), dephosphorylated tau (Tau1), phosphorylated tau (pT231, pS404 and PHF1) and β-actin. Theminor band of tau
(arrow) was observed inWT, but not KI-P301L tau neurons. Quantiﬁcation of the minor tau band (B) and total tau relative to β-actin (C). (D) Tau proﬁle inWT and KI-P301L tau neurons
after lambda phosphatase treatment at 5, 8, 12 and 14 DIV analysed onWestern blots using an antibody to total tau (DAKO) and β-actin. (E) RT-PCR showing the relative expression of
three-repeat (3R) and four-repeat (4R) tau in WT and P301L tau neurons at 5, 8, 12 and 14 DIV. (F) Quantiﬁcation of the 4R/3R tau ratio determined by RT-PCR in WT and P301L tau
neurons. Mean ± SEM (n = 3–6, Student t-test, P b 0.001***).
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sistent betweenwild-type and P301L tau-expressing neurons indicating
that, at least up to 14DIV, the P301Lmutation does not affect alternative
splicing of tau in cultured neurons.
To conﬁrm and extend these observations, we extracted RNA from
wild-type and P301L tau-expressing neurons at 5, 8, 12, and 14 DIV.
Tau cDNAwas analysed using primers spanning exons 9 to 13 to differ-
entiate between alternatively spliced tau species that either lacked (3R)
or included (4R) exon 10. The intensity of the PCR products correspond-
ing to 3R and 4R tau isoformswas quantiﬁed after separation on agarose
gels (Fig. 3E, F). Notably, the 4R/3R tau ratio remained below 0.5 up to 8
DIV, indicating a predominance of 3R tau. However, by 12 DIV, the
4R/3R tau ratio increased, showing that approximately equal amounts
of 4R and 3R tau are expressed at this stage. The data suggest that a
switch occurs between 8 and 12 DIV that drives the production of 4R
isoforms in cultured primary neurons. These results thus conﬁrm our
ﬁndings that wild-type and P301L tau-expressing neurons exhibit
similar 4R/3R isoform ratios, and show that the P301L mutation does
not affect the normal splicing of tau.
To further investigate the cause of the reduced phosphorylation of
tau, protein phosphatase (PP) 1 and PP2A were analysed, since these
have both been shown to dephosphorylate tau (Goedert et al., 1995;
Gong et al., 1994; Liu et al., 2005). We quantiﬁed PP1 and PP2A inwild-type and P301L tau-expressing neurons relative to β-actin
(Fig. S3). This analysis showed that the amount of PP1 was decreased
by 32% in neurons expressing P301L tau, whereas the amount of PP2
was unchanged, relative to wild-type neurons.
P301L tau and microtubule binding in cortical neurons
The microtubule-binding repeat domain of tau is important for its
association with tubulin and 4R tau has been reported to bind more
tightly to microtubules than 3R tau (Butner and Kirschner, 1991).
Since the P301L tau mutation is located in exon 10, which encodes the
fourth microtubule-binding repeat, it is possible that the P301L muta-
tion could affect interactions between tau andmicrotubules. To address
this question, lysates of wild-type and P301L tau cortical neurons (12
DIV) were fractionated into microtubule-bound, and unbound compo-
nents, based on their differential solubility (Ding et al., 2006) and
analysed on Western blots probed with antibodies for tau and tubulin
(Fig. 4A). The percentage of tau and tubulin in themicrotubule fractions
relative to the input was quantiﬁed for each condition (Fig. 4B, C). The
results show a statistically signiﬁcant decrease in the amount of tau
present in the microtubule fraction of KI-P301L tau neurons (14.6% for
WT, 6.9% for P301L, P b 0.01) (Fig. 4B). This ﬁnding is in agreement
with previous in vitro studies describing reduced microtubule binding
Fig. 4. Microtubule-binding properties of wild-type and P301L tau in cortical neurons.
(A) Wild-type (WT) and knock-in P301L (KI-P301L) tau neuronal lysates were separated
into microtubule-bound and unbound fractions, and analysed onWestern blots using an-
tibodies to total tau and tubulin. Quantiﬁcation of the percentage of total tau (B) or tubulin
(C) present in themicrotubule (MT) fraction. (D)Quantiﬁcation ofmicrotubule-bound tau
relative to tubulin, expressed relative toWT tau. Data are shown asmean±SEM(n=7–8,
Student t-test, P b 0.01**).
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Hong et al., 1998). No difference was found in the amount of tubulin
present in the microtubule fraction (Fig. 4C). The results thus conﬁrm
that the P301L mutation reduces the capacity of tau to bind to microtu-
bules under physiological conditions.
P301L tau and membrane localisation
We have previously reported that phosphorylation of tau affects its
intracellular localization and that decreased tau phosphorylation
increases its association with membranes (Pooler et al., 2012). Since
KI-P301L-derived tau is relatively hypophosphorylated we determined
if the presence of the P301L mutation could affect tau trafﬁcking to
the membrane in neurons. Lysates of wild-type and KI-P301L tau
cortical neurons (14 DIV), and brain tissue from mice of four months
of age, were separated into cytosolic and membrane fractions and
analysed on Western blots probed with antibodies to total tau (DAKO)
and dephosphorylated tau (Tau1) (Fig. 5A, B). The neurons from
wild-type and KI-P301L tau neurons at 14 DIV contained tau species re-
sembling those in 8 DIV neuronal cultures (Fig. 3A), in which KI-P301L
tau neurons lack the slower migrating tau species (Fig. 5A, arrow). KI-
P301L taumouse brain also lacked this tau species andmigrated slightly
faster thanwild-type tau (Fig. 5B, arrow). Quantiﬁcation of dephosphor-
ylated (Tau1), relative to total tau, revealed a signiﬁcant increase in four
month old KI-P301L tau brain, indicating increased tau dephosphoryla-
tion (Fig. 5D), but therewas no statistically signiﬁcant change in Tau1 in
14DIV neurons (Fig. 5C). These results suggest that changes in tau phos-
phorylation are age-dependent and could be related to the increasing
amount of 4R tau expressed in adult mice. The proportion of P301L
tau in the membrane fraction was similar to that of wild-type tau in
both neurons and adult mouse brain (Fig. 5D, F) suggesting that the
hypophosphorylated state of P301L tau does not affect its trafﬁcking
to the membrane.
Discussion
In a previous study of adult KI-P301L mice, which express the tau
mutation at physiological levels, we reported a reduction in tau phos-
phorylation in adult mouse brain and age-dependent changes in axonal
mitochondrial transport in isolated tibial nerve (Gilley et al., 2012).
Here, we have investigated the effects of the P301L tau mutation in
mouse cortical neurons from KI-P301L mice. Notably, we found that
P301L tau expression reduces the number of axonal mitochondria, al-
though their anterograde and retrograde directional kinetic parameters
were similar to wild-type neurons. Approximately 20% of mitochondria
were motile, irrespective of whether wild-type or mutant tau was
expressed, similar to other reports of mitochondrial transport in sciatic
nerve (Magrane et al., 2014), hippocampal neurons (Shao et al., 2013)
and dopaminergic neurons (Kim-Han et al., 2011). However, the motile
mitochondria in neurons harbouring P301L tau had an increased
volume. It is conceivable that the larger volume of individual moving
mitochondria is masked when measuring the size of all mitochondria
(i.e., both motile and stationary) due to the large proportion of these
stationary organelles. This increase in mitochondrial volume in P301L
tau-expressing neurons is in agreement with a previous study of mice
overexpressing the P301S tau mutation, in which the number of mito-
chondria in spinal cord motor neurons of adult P301S tau mice were
reduced and also appeared to be swollen (Yoshiyama et al., 2007).
However, contrasting results have also been reported with no change
in the number of mitochondria in P301L tau over-expressing mice at
18 months of age (David et al., 2005). Interestingly, the angle which
deﬁnes the orientation of the mitochondria in the axon was greater in
neurons expressing KI-P301L tau. Such a change in orientation could
lead to a temporary blockage or reduced ﬂow of axonal mitochondria
that, even if not affecting their overall transport kinetics, could increase
Fig. 5. The P301L mutation in tau does not affect its membrane localization. Lysate, cytosol and membrane fractions of (A) 14 days in vitro (DIV) mouse cortical neurons and (B) adult
mouse brain (4 months old), were analysed on Western blots probed with antibodies against total tau, dephosphorylated tau (Tau1) and β-actin. Quantiﬁcation of dephosphorylated
tau relative to total tau in lysates of neurons (C) and brain tissue (D). The ratio of the amount of tau localised in the membrane and the cytosol was calculated for wild-type (WT) and
knock-in P301L (KI-P301L) tau-expressing neurons (E), and brain tissue (F). Data are shown as mean ± SEM (n= 11 for neurons, n = 6 for brain tissue, Student t-test, P b 0.001***).
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mitochondria in the axon.
The effect of tau on mitochondrial function and dynamics has also
been studied in neuroblastoma cells over-expressing wild-type and
P301L tau (Schulz et al., 2012). These authors reported that the P301L
tau mutation results in a deﬁcit in mitochondrial complex 1, accompa-
nied by reduced ATP levels, and increased susceptibility to oxidative
stress. Furthermore, overexpression of P301L tau in neuroblastoma
cells resulted in perinuclear clustering of mitochondria and reducedmi-
tochondrial movement (Schulz et al., 2012). P301L tau has also been
shown to decrease the rates of both ﬁssion and fusion of mitochondria,
an observation corroborated by parallel reductions in the amounts of
mRNA encoding proteins involved in these processes in neuroblastoma
cells (Schulz et al., 2012). Taken together, these results suggest that
P301L tau may have a fundamental effect on axonal mitochondria.We found that P301L tau expression results in the appearance of
hypophosphorylated tau in cultured cortical neurons, similar to our
ﬁndings in adult mouse brain (Gilley et al., 2012). This suggests that
the observed decrease in tau phosphorylation in the KI-P301L tau
mice is an early event that is maintained into adulthood. To investigate
the cause of the reduced phosphorylation of tau, two enzymes known to
dephosphorylate tau, PP1 and PP2A, were examined. We found that
expression of these phosphatases was not increased in KI-P301L mice.
Instead we observed a reduction of 32% in the amount of PP1, and no
change in PP2A, suggesting that hypophosphorylation of tau in
KI-P301L mice is not due primarily to increased expression of these
phosphatases. It is conceivable that decreased tau phosphorylation
could be the consequence of reductions in the amounts or activities of
tau kinases or, alternatively, an altered tau conformation that prevents
its physiological phosphorylation. For example, reduced PP1C activity
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(GSK-3), which reduces GSK-3 activity (Manser et al., 2012). Since
GSK-3 is a tau kinase (Hanger et al., 1992), reduced PP1C could result
in decreased tau phosphorylation.
We also analysed the possible effect of the P301L mutation on tau
alternative splicing by determining the 4R/3R tau ratio in neurons at
different ages in vitro. We conﬁrmed here that physiological expression
of P301L does not interfere with normal tau splicing in cortical neurons,
a ﬁnding in line with previous in vitro (D'Souza et al., 1999) and in vivo
(Hutton et al., 1998) studies.
The effect of the P301L mutation on tau-microtubule binding prop-
erties of tau was determined in cortical neurons. Our previous compar-
ison of wild-type and KI-P301L tau in adult mouse brain showed a
decreased amount of P301L tau in microtubule-containing fractions
(Gilley et al., 2012). This is recapitulated here in 12 DIV cortical neurons
derived from embryonic brain tissue in which the amount of tau bound
to microtubules was signiﬁcantly reduced in KI-P301L tau neurons,
whereas the amount of tubulin was unaffected. These results are in
agreement with previous reports suggesting that P301L tau has a re-
duced ability to bind to microtubules (D'Souza et al., 1999;
Dayanandan et al., 1999; Hong et al., 1998). The tau/tubulin ratio was
diminished in KI-P301L neurons but this difference did not reach signif-
icance. The reason for this could be explained by the fact that 12 DIV
cortical neurons express approximately 50% of tau as 3R isoforms,
which lack the part of the microtubule-binding domain encoded by
exon 10. In contrast, mouse tau in adult KI-P301L brain is comprised
of 4R tau isoforms, which includes the affected residue, and shows a
signiﬁcant decrease in the tau/tubulin ratio (Gilley et al., 2012).
Phosphorylation of tau reduces its association with the neuronal
plasma membrane (Pooler et al., 2012). Since P301L tau appears to be
less phosphorylated in adult KI-P301L mice and also in cortical neurons
derived from these animals, we investigated whether the P301L muta-
tion affected the intracellular localization of tau. We found that the
relative proportion of tau in membrane and cytosolic fractions of both
cultured neurons and adult mouse brain was similar for wild-type and
P301L tau. This shows that tau hypophosphorylation caused by the
presence of themutation does not inﬂuence its intracellular localisation.
However, phosphorylation in theN-terminal half of tau has been shown
to inﬂuence its ability to localise tomembranes (Pooler et al., 2012) and
therefore, since P301L is in the C-terminal region of tau, it is possible
that the phosphorylation sites affected by the presence of this mutation
may not have a signiﬁcant inﬂuence on the ability of tau to associate
with neuronal membranes. Interestingly, the increase in dephosphory-
lated tau was observed only in 4 month old KI-P301L brains, and not
in cultured cortical neurons. This suggests an age-dependent increase
in dephosphorylated tau, possibly related to an increase in 4R tau
isoforms containing the P301L mutation in adult mice.
Conclusions
Expression of endogenous levels of P301L tau in mouse cortical neu-
rons reduces tau phosphorylation but does not inﬂuence the association
of tau with membranes or tau splicing. P301L tau expression results in
reduced numbers of axonal mitochondria and increased volume of indi-
vidual motile mitochondria, without affecting their kinetic parameters.
Our results imply that some of the effects of P301L tau onmitochondria
reported in previous studies could be due to over-expression of mutant
tau. Signiﬁcantly, physiological expression levels of P301L tau result in
relatively modest changes to mitochondria and tau phosphorylation
state in both cultured neurons and in adult mice. Understanding the
mechanisms that lead to reduced numbers and larger volumes ofmotile
mitochondria due to the presence of P301L tau warrants further
investigation since disruption of mitochondrial function is likely to be
severely detrimental to neuronal survival.
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